Cancer immunotherapy: how low-level ionizing radiation can play a key role

Janiak, Marek K.; Wincenciak, Marta; Cheda, Aneta; Nowosielska, Ewa M.; Calabrese, Edward J.

doi:10.1007/s00262-017-1993-z

Cited by 52 publications

(47 citation statements)

References 207 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experiential data suggest that the combination of radiotherapy alongside the immunotherapeutic agents can produce the synergistic effects (Figure 3) [61,62]. From all the above-stated information, it has become clear that recent developments in radiation therapy [61,63,64] may have proven to be the most critical part in the successful development of cancer vaccine.…”

Section: Radiation Therapy: Application In Medical Researchmentioning

confidence: 99%

“…It is been in under the clinical trials for the various types of cancers [65][66][67] however, due to the issues of safety and other regulatory affairs it is under development at industrial level [58]. On the other side, results of current clinical trials of using the various irritated vaccines for numerous pathogens and tumors has attracted the researcher and scientific world towards the preparation of various radiationbased vaccine for various infected and non-infected diseases [61,62,64,68]. The ongoing effective development of irradiated vaccines for malaria and influenza have exhibited the attainability of this approach, and have shown the promising results alongside the advantages of the radiation therapy by overcoming the limitation of existing facilities without using any sophisticated technological approach [69,70].…”

Section: Radiation and Vaccine Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity against Malaria Infection

Tandel¹,

Trivedi²,

Krishnan³

et al. 2020

Ionizing and Non-Ionizing Radiation

View full text Add to dashboard Cite

Among the numerous infectious diseases, malaria remains a major health challenge. Despite the various approaches adopted for the vector control and availability of antimalarial drugs, the success of malaria eradication is dampened by the spread of drug and insecticide resistance, unavailability of proper diagnostic treatment and successful vaccine. Among the various approaches, vaccination with the aim of developing protective immunity is the most suited, safe and reliable approach for the entire mankind. Numerous approaches are in use for vaccine development; however, they suffer from the drawbacks that immunity developed is short lived and are both species-and stage-specific. Of late, radiation sterilization has drawn the attention in the vaccine development due to its advantages over the conventional methods, and successful clinical trials of irradiated vaccines against the pathogens and tumor. Recently, a novel approach of genetically attenuated sporozoites (PfRAS, PfSPZ, PFSPZ-GA1 sporozoites vaccines) has shown promising results by generating protective immunity against the homologous and heterogenous infection in the clinical trials. Radiation techniques have also been beneficial in controlling the insects by sterility technique. In this chapter, we have recapitulated the role of radiation biology in the malaria vaccine development with its current status and future challenges associated with the development of radiation attenuated parasite vaccine.

show abstract

Section: Radiation Therapy: Application In Medical Researchmentioning

confidence: 99%

Section: Radiation and Vaccine Developmentmentioning

confidence: 99%

Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity against Malaria Infection

Tandel¹,

Trivedi²,

Krishnan³

et al. 2020

Ionizing and Non-Ionizing Radiation

View full text Add to dashboard Cite

show abstract

“…The knowledge gained about immune modulation by intermediate and low dose of radiation might be transferred in the future to tumor immunological questions. Some experiments have already been performed that indicate that irradiation with low dose retards the development of neoplasms in humans and experimental animal models . However, radiation protection issues have always to be respected and carefully to be considered when approaching this way alternative radiation protocols.…”

Section: Low Doses Of Radiation and Inflammationmentioning

confidence: 99%

Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases

Frey

Rückert

Deloch

et al. 2017

Immunological Reviews

149

127

View full text Add to dashboard Cite

Ionizing radiation is often regarded as an element of danger. But, danger responses on the cellular and molecular level are often beneficial with regard to the induction of anti-tumor immunity and for amelioration of inflammation. We outline how in dependence of radiation dose and fraction, radiation itself-and especially in combination with immune modulators-impacts on the innate and adaptive immune system. Focus is set on radiation-induced changes of the tumor cell phenotype and the cellular microenvironment including immunogenic cancer cell death. Mechanisms how anti-tumor immune responses are triggered by radiotherapy in combination with hyperthermia, inhibition of apoptosis, the adjuvant AnnexinA5, or vaccination with high hydrostatic pressure-killed autologous tumor cells are discussed. Building on this, feasible multimodal radio-immunotherapy concepts are reviewed including overcoming immune suppression by immune checkpoint inhibitors and by targeting TGF-β. Since radiation-induced tissue damage, inflammation, and anti-tumor immune responses are interconnected, the impact of lower doses of radiation on amelioration of inflammation is outlined. Closely meshed immune monitoring concepts based on the liquid biopsy blood are suggested for prognosis and prediction of cancer and non-cancer inflammatory diseases. Finally, challenges and visions for the design of cancer radio-immunotherapies and for treatment of benign inflammatory diseases are given.

show abstract

“…Combination therapy to focus the adaptive immune system on the relevant cancer antigens (such as active vaccination together with checkpoint blockade, as referenced above) together with measures to prevent tumour escape (such as MDSC down‐regulation, neutralization of the inhibitory activity of the tumour microenvironment, etc.) (for reviews, see Refs ), amplification of anti‐tumour innate immunity and judicious use of immunoenhancing radio‐ and chemotherapy, as well as possible ‘epigenetic rejuvenation’ of ‘exhausted’ CD8 + T‐cells, offer hope that efficient anti‐cancer immunity could be monitored, modulated and maintained by modifying therapies appropriately over the course of treatment, and thus elicit cures in all patients. Given the remarkable success of even some single‐agent immunotherapies in certain patients which, considering the redundancy of immune control mechanisms and the great propensity of cancer to evolve resistant variants, is even more remarkable, it is all the more likely that future protocols based on individual patient factors will increase treatment success rates.…”

Section: Patient Monitoringmentioning

confidence: 99%

Immune correlates of clinical outcome in melanoma

Pawelec

2017

Immunology

View full text Add to dashboard Cite

SummaryMelanoma has long been recognized as a potentially immunogenic tumour, but only recently has it become clear that the reason for this resides in its many ultraviolet (UV)-induced mutations and expression of multiple autoantigens which can be targeted by the immune system. The first successful applications of immune-based treatments included passive immunotherapy using high-dose interleukin (IL)-2 and/or adoptive transfer of natural killer (NK)-cells, as well as active immunotherapy using whole cell-derived or peptide vaccines. In the intervening decades, it has become clear that these approaches can lead to durable responses in stage III/IV melanoma, and even to functional cures -but only in a vanishingly small fraction of patients. With the advent of immune checkpoint blockade first with anti-cytotoxic T-lymphocyte 4 (CTLA-4), then with anti-programmed cell death 1 (PD-1) antibodies, and combinations thereof, the small percentage of responding patients may be increased to half, a major accomplishment in this refractory disease. Improved techniques for identifying mutation-derived neoantigens and thus more sophisticated active immunotherapies, probably combined with checkpoint blockade, currently hold great promise for further increasing the fraction of responding patients. As additional immunomodulatory antibodies and therapies become available, it will be increasingly important to develop diagnostic tools to determine which particular therapy is likely to elicit the best response for the individual patient. Practically speaking, therapy selection and efficacy monitoring on the basis of the results of a blood test would be most desirable. The purpose of this review is to consider the feasibility of identifying 'immune signatures' for predicting responses and determining mechanisms responsible for success or failure of these immunotherapies.

show abstract

Cancer immunotherapy: how low-level ionizing radiation can play a key role

Cited by 52 publications

References 207 publications

Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity against Malaria Infection

Application of Radiation Technology: A Novel Vaccine Approach to Induce Protective Immunity against Malaria Infection

Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases

Immune correlates of clinical outcome in melanoma

Contact Info

Product

Resources

About